Abstract
Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications, posaconazole is known to have many side effects and drug-drug interactions. We present a patient who developed rhabdomyolysis after being started on posaconazole for prophylaxis in the setting of relapsed acute myeloid leukemia.
| Original language | English (US) |
|---|---|
| Journal | Journal of Investigative Medicine High Impact Case Reports |
| Volume | 5 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2017 |
Keywords
- AML
- Acute myeloid leukemia
- Posaconazole
- Rhabdomyolysis
ASJC Scopus subject areas
- Epidemiology
- Safety, Risk, Reliability and Quality
- Safety Research
Fingerprint Dive into the research topics of 'Rhabdomyolysis following initiation of posaconazole use for antifungal prophylaxis in a patient with relapsed acute myeloid leukemia: A case report'. Together they form a unique fingerprint.
Cite this
Mody, M. D., Ravindranathan, D., Gill, H. S., & Kota, V. K. (2017). Rhabdomyolysis following initiation of posaconazole use for antifungal prophylaxis in a patient with relapsed acute myeloid leukemia: A case report. Journal of Investigative Medicine High Impact Case Reports, 5(1). https://doi.org/10.1177/2324709617690747